Avaliação da resposta broncodilatadora por meio do sistema de oscilometria de impulso e espirometria em crianças e adolescentes com fibrose cística

Rev Paul Pediatr rpp Revista Paulista de Pediatria Rev. paul. pediatr. 0103-0582 1984-0462 Sociedade de Pediatria de São Paulo RESUMO Objetivo: Investigar o efeito do broncodilatador na mecânica respiratória e função pulmonar de crianças e adolescentes com fibrose cística. Métodos: Estudo transversal em crianças e adolescentes com fibrose cística clinicamente estáveis, com idade entre seis e 15 anos. Os participantes realizaram avaliações por meio do sistema de oscilometria de impulso e espirometria antes e 15 minutos depois da inalação de broncodilatador. Foi aplicado o teste Kolmogorov-Smirnov para verificar a distribuição da amostra. Para comparar os dados antes e depois do broncodilatador foram utilizados os testes t de Student e Wilcoxon. Resultados: Participaram do estudo 54 indivíduos com média de idade de 9,7±2,8 anos. Houve melhora estatisticamente significativa nos parâmetros do oscilometria de impulso e espirometria após a inalação com broncodilatador. No entanto, de acordo com recomendações da American Thoracic Society (ATS) e European Respiratory Society (ERS) (2020 and 2021), essa melhora não foi suficiente para classificar como reposta broncodilatadora. Conclusões: O uso de medicamento broncodilatador melhorou a mecânica respiratória e função pulmonar de crianças e adolescentes com fibrose cística, no entanto a maioria da amostra não apresentou resposta ao broncodilatador de acordo com as recomendações da ATS/ERS. INTRODUCTION Bronchodilators (BDs) are commonly used in treating respiratory diseases to relax airway smooth muscles and alleviate symptoms of bronchoconstriction, such as dyspnea.1,2 The use of BDs in diseases like asthma and chronic obstructive pulmonary disease (COPD) is well-established in the scientific literature.1,3 However, the effectiveness of BDs in people with cystic fibrosis (pwCF) remains a topic of debate, despite being frequently prescribed in clinical practice.4,5 Barry and Flume (2017) raised the following arguments for the prescription of BD to individuals with cystic fibrosis (CF): the presence of asthma associated with CF; the obstructive pulmonary characteristic of CF; the bronchoconstriction caused by inhalation of medications such as antibiotics and hypertonic saline solution; and the mucociliary clearance effect.5 Despite these theoretical issues, the authors affirmed that the evidence for BD use in CF must be better explored.5 Two systematic reviews were conducted concerning BD use in pwCF.4,6 One focused on the effect of long-acting inhaled BDs and analyzed four clinical trials.4 The authors concluded that there was no improvement in the forced expiratory volume in one second (FEV1) and the quality of the evaluated papers was poor.4 The other systematic review investigated short-acting inhaled BDs and analyzed 11 clinical trials.6 Although the trials showed an improvement in FEV1, it was not reported if such improvement achieved the threshold for a bronchodilator response (BDR) according to the American Thoracic Society and European Respiratory Society (ATS/ERS)7. Both systematic reviews informed that there was little evidence on the BD effect in CF. Nevertheless, none of the studies included in those systematic reviews evaluated BD effects on respiratory mechanics. One way of measuring the BD effect on respiratory mechanics is via the impulse ocillometry system (IOS), a tool that assesses the airway's resistance and reactance during tidal breathing.8 The ERS recently released a document that establishes cut-off points to identify if changes in respiratory mechanics are a consequence of BD inhalation.9 Since IOS does not require forced expiration, it can be used in conjunction with spirometry to detect a BDR in pwCF.10 This study aimed to investigate the BDs effect on the spirometry and IOS parameters of children and adolescents with CF. As the BDs’ mechanism of action is to relax the airway smooth muscles, we hypothesized that there would be an improvement in airway resistance after BD inhalation. METHOD This is a cross-sectional study performed in a CF referral center in Brazil, from June 2017 to November 2018. It was approved by the referral center's Ethics Committee (CAAE: 80800217.4.0000.5361), and written informed consent was obtained from the patients and their guardians. This study included individuals aged six to 15 years with a confirmed CF diagnosis12, and the convenience sampling method was used. Individuals were excluded from the sample if they could not use BD at the moment of evaluation or if they presented an acute pulmonary exacerbation as identified by the Cystic Fibrosis Clinical Score (CFCS)12 and the Cystic Fibrosis Foundation Score (CFFS).13 The following data were obtained from the medical records: pathogen colonization (of at least one pathogen); genetic variant (with the presence of at least one allele with F508del variant); and disease severity (categorized as "excellent", "good", "average", "poor", or "severe" according to the Schwachman-Doerschuk Score [SDS]).14 The use of BDs and/or steroid medications commonly prescribed to treat asthma was also recorded. Anthropometric measurements of weight, height, and body mass index (BMI) were collected. The BMI was presented in kg/m2 and z-scores (the latter, according to World Health Organization).15 Participants were categorized as "eutrophic", "overweight", "obesity", "thinness", or "severe thinness".15 Respiratory mechanics and pulmonary function were evaluated by IOS and spirometry, respectively. Following the ATS/ERS recommendations,7,9 these evaluations were performed on a pneumatograph Master Screen IOS (Erich Jaeger, Würtzburg, Germany®). In order to avoid interference of forced maneuvers on the oscillometric parameters, IOS evaluation was always performed before spirometry. The oscillometric parameters were impedance at 5Hz (Z5), resistance at 5Hz (R5), resistance at 20Hz (R20), and reactance at 5Hz (X5). The R5 and R20 parameters are commonly referred to as total airway resistance and central airway resistance, respectively. The reference IOS parameters were computed via Assumpção et al. reference equation16 and each parameter was presented in absolute and predicted percentage (pred%). Regarding spirometry, the following parameters were recorded: forced vital capacity (FVC), FEV1, and forced expiratory flow at 25 to 75% of FVC (FEF25-75). The reference values were obtained through the Global Lung Function Initiative (GLI)17, and the parameters were presented in absolute values and as pred%. The evaluation occurred at two moments: Pre-bronchodilator (pre-BD) and 15 minutes post-bronchodilator (post-BD). During the IOS evaluation, each individual underwent three measurements of 20 seconds of breathing in tidal volume. The absolute difference in the R5 parameter between two measurements for the same individual was never larger than 10%. For everyone, the measurement with the lowest R5 value was selected for statistical analysis. Regarding the spirometry evaluation, three acceptable and two reproducible maneuvers were recorded.9 The participants suspended the use of BDs 12 hours before the evaluation. During the assessment, all individuals used metered-dose inhalers with plastic spacer devices to inhale 400 μg of salbutamol. This evaluation was repeated at least 15 minutes after BD inhalation. A BDR was determined according to the ATS/ERS recommendations.9,10 For the IOS, a BDR is characterized by a reduction of 40% in R5 or an increase of 50% in X5.9 In the spirometry evaluation, a BDR occurs when the differences between pre-BD and post-BD measurements of FEV1 and FVC are larger than 10% of the predicted values, according to ATS/ERS formula.10 The data was analyzed through Statistical Package for Social Sciences (SPSS) version 20.0© IBM software. The Kolmogorov-Smirnov test was applied to verify data distribution. The paired Student´s t-test and the Wilcoxon Signed Rank Test were used to compare data before and after BD. The significance level of all tests was fixed at 5%. A Student's t-test comparing R5% before and after BD inhalation was used to calculate the effect size. The test showed an effect size of 0.52 in a sample of 54 individuals. We then used this value in the G*Power software to compute the power of the study and the result was 96%. Patients were categorized into two groups: individuals with FEV1 at least 80% of the predicted value (G1); and individuals with FEV1 below 80% of the predicted value (G2). The independent Student's t-test and Mann-Whitney U test were used to compare the Δpre-post values between the groups. RESULTS Eighty-three children and adolescents with CF, followed up at the referral center, were in the age group to undergo pulmonary function assessment and all were invited to this study. However, only 57 consented to participate and were assessed, but three individuals were excluded due to acute pulmonary exacerbations. Therefore, the study included 54 children and adolescents. Observing the baseline values (pre-BD), we noted that 53.8% of patients had FEV1 lower than 80% of the predicted value, while 74.1% had X5 above 150% of the predicted value. Their characteristics are shown in Table 1. Table 1 Characterization of the studied sample. Characteristics Total sample (n=54) Age (years) 9.7±2.8 Female n (%) 26 (48.1) BMI (kg/m2) 16.2±2.3 BMI z-score -0.6±1.2 Overweight n (%) 5 (9.3) Eutrophic n (%) 45 (83.3) Thinness n (%) 4 (7.4) SDS classification n (%) Excellent 31 (57.4) Good 13 (24.1) Average 7 (13.0) Poor 3 (5.6) Variant classification n (%) F508del homozygous 16 (29.6) F508del heterozygous 26 (48.1) Others 12 (22.2) Colonization n (%) 41 (75.9) Data are presented as mean±standard deviation or as frequency (%). BMI: body mass index; SDS: Schwachman-Doerschuk Score; F508del: cystic fibrosis´ variant. Figures 1 and 2 present the spirometric and oscillometric analyses. All the parameters showed statistical differences between pre- and post-BD, indicating improvement after BD inhalation. However, according to the ATS/ERS10 recommendations, only six individuals (11.1%) presented a positive BDR in FVC and FEV1 parameters. FEF25-75 was the spirometric parameter that had the greatest difference. Table 2 presents the obtained differences between pre- and post-BD assessment. Figure 1 Comparison of spirometric parameters between pre- and post-BD. Figure 2 Comparison of oscillometric parameters between pre- and post-BD. Table 2 Difference between pre- and post-bronchodilator (Δpre-post). Δpre-post Δpre-post FVC (L) 0.05 (0.01 to 0.08) Z5 -0.14 (-0.19 to -0.09) FVC% 2.07 (0.55 to 3.60) Z5% -31.99 (-42.83 to -21.15) FEV1 (L) 0.06 (0.03 to 0.09) R5 -0.13 (-0.16 to -0.09) FEV1% 3.21 (1.54 to 4.88) R5% -19.95 (-26.19 to -13.71) FEF25-75 (L/s) 0.13 (0.06 to 0.21) R20 -0.04 (-0.06 to -0.03) FEF25-75% 6.44 (3.02 to 9.85) R20% -8.27 (-11.54 to -5.00) --- --- X5 0.07 (0.03 to 0.10) --- --- X5% -46.17 (-68.33 to -24.01) Mean (95%CI): mean (95% confidence interval); Δpre-post: difference between pre-and pre-bronchodilator evaluation; FVC: forced vital capacity; FEV1: forced expiratory volume in one second; FEF25-75: forced expiratory flow at 25% to 75% of FVC; Z5: impedance at 5 Hz; R5: total resistance airway at 5Hz; R20: central resistance airway at 20Hz; X5: reactance at 5 Hz. Regarding the oscillometric parameters, Z5 and R5 had the greatest post-BD improvements. In addition, X5 had a difference of about 46 points in pred%. Nonetheless, by the ERS9 recommendation, only three individuals (5.5%) showed a positive BDR in R5 and five individuals (9.2%) showed a positive BDR in X5. Out of the 54 individuals, 25 belonged to G1 (FEV1≥80%) and 29 to G2 (FEV1<80%). Comparing the two groups, there was no statistically significant difference. Concerning the use of BDs and/or steroid medications: three individuals used formoterol fumarate with budesonide; three used salbutamol; one used salmeterol with fluticasone; one used an unspecified inhaled BD; nine used nasal budesonide, and two used fluticasone. DISCUSSION The individuals in our study had a high SDS, meaning that they had a mild disease severity. Still, most pre-BD had FEV1< lower than 80% of the predicted value and X5 higher than 150% of the predicted value, indicating impairment of the respiratory system at baseline. Also, more than 70% of the individuals were colonized by some pathogen. Regarding the BD effect, the current study showed a statistically significant improvement in spirometric and oscillometric parameters after BD inhalation. However, in both evaluations, only a few individuals achieved a positive BDR according to the ATS/ERS recommendations.9,10 Typically, the BDR evaluation occurs through a forced expiratory maneuver in spirometry. Although the BDR evaluation is widely used for individuals with asthma, the ATS/ERS's most recent document states that more evidence is needed regarding its cut-off points for children and young adults.10 Moreover, the current criteria for a positive BDR do not seem sensitive in detecting different types of COPD.10 Such an observation was also made by Muramatu et al., where only a few (7.7%) of the 312 spirometric data of children and adolescents with CF presented a BDR.18 Additionally, the authors observed improvement in the predicted percentage of FVC, FEV1, and FEF25-75.18 The BDR observed in around 10% of our pwCF sample is similar to the prevalence of asthma in the Brazilian population.19 Therefore, those individuals with CF presenting a positive BDR may be investigated for the most frequent asthma phenotypes (Th2), which include allergic, eosinophilic, and mixed asthma.20 In this study, even though most individuals did not show a BDR, the spirometric parameters improved after BD inhalation. Among all the spirometry parameters, FEF25-75 showed the greatest difference between pre- and post-BD inhalation (about 0.13 liters), suggesting an improvement in the airflow of peripheral airways. However, FEF25-75 is often not considered in the BDR evaluation, given that the ATS/ERS recommends analyzing only FVC and FEV1.10 Besides spirometry, the IOS has also been used to evaluate BDR.21,22 Although a few studies determined cut-off points for BDR through oscillation assessment — with ERS affirming that more researches with a healthy population are necessary to provide better cut-off points9 — the IOS complements spirometry and has been studied in individuals with asthma.21,22 Still, a small number of studies consider the use of IOS for BDR evaluation in people with CF. For instance, Hellinckx et al. evaluated the spirometric and oscillometric parameters of 20 individuals with CF aged 6.5 to 17.5 years.23 No statistical differences were found in FEV1 before and after BD inhalation; however, there was an improvement in resistance R6 (6Hz) and reactance X6 (6Hz) after BD, corroborating data from our study. It should be noted that the study by Hellinckx et al.23 was conducted before the ERS9 recommendation; therefore, they have not determined how many individuals presented a positive BDR in the oscillometric parameters. Recently, Ozturk et al. used IOS to evaluate the respiratory mechanics of people with CF.24 In one of their analyses, BDR was evaluated in 33 children with CF (146.7±[standard deviation] 52.5 months of age) through IOS and spirometry before and 15 minutes after the inhalation of 200 μg bronchodilator medication.24 The authors used the older ATS/ERS reference from 200525 to determine a positive BDR, and only five children had the required improvement of at least 12% in FEV1. In accordance with our findings, Ozturk et al. reported an improvement in all IOS parameters after BD inhalation. However, similarly to the previously mentioned study of Hellinckx et al., the authors have not used cut-off points to determine whether a child had positive or negative BDR in the IOS evaluation. Among all the different IOS parameters evaluated in this study, Z5 and R5 had larger differences between pre- and post-BD inhalation — about 0.14 and 0.13 kPa/L/s, respectively. Since Z5 refers to the sum of all forces opposing the waves emitted by IOS, and R5 corresponds to the total airway resistance, the results observed in the present study suggest that there was a global change in the respiratory mechanics, implying an improvement in the peripheral airway.26 Despite the results not achieving the ERS recommendation,9 this improvement caused by salbutamol may contribute to the clinical condition of pwCF, assisting during physical exercise and in the penetration of other inhaled medicines such as mucolytic agents and inhaled antibiotics. As a limitation of the present study, it is worth mentioning that the number of individuals with asthma symptoms was not controlled by a questionnaire. Furthermore, the disease severity was established with the SDS,14 a score that was elaborated in the 1960s, and that perhaps, due to the recent treatment advances, does not accurately represent the CF severity anymore. Although the BDR is frequently used as a criterion for asthma diagnosis, our study shows that its response may not be as expressive in people with CF. Further studies could investigate whether BD shows a clinically meaningful effect on pwCF, in other words, if they report positive or negative changes in their clinical condition after BD inhalation. This information could support the prescription of BD, once most referral centers worldwide routinely recommend BD and inhaled corticosteroids to pwCF.5 The ideal situation would be to individually verify if the patients inform changes in their daily living after BD inhalation and present positive BDR, which could mean a CF-asthma overlap syndrome.27 In conclusion, the individuals assessed in this study did not meet the BDR classification criteria. However, the results of our study showed that the use of BD in children and adolescents with CF might lead to improvements in pulmonary volumes as well as airway resistance, which corroborates our primary hypothesis. Acknowledgments We gratefully acknowledge Matheus Jun Ota for his contribution and suggestions on English writing. Funding This study was supported by the Foundation for Research and Innovation of the State of Santa Catarina, FAPESC/Brazil (PAP UDESC, Public Call N° 27/2020, Grant Term 2021TR809) and Coordination for the Improvement of Higher Education Personnel (CAPES). Declaration The database that originated the article is available with the corresponding author. REFERENCES 1 Cazzola M Page CP Calzetta L Matera MG Pharmacology and therapeutics of bronchodilators Pharmacol Rev 2012 64 450 504 https://doi.org/10.1124/pr.111.004580 1 Cazzola M, Page CP, Calzetta L, Matera MG. Pharmacology and therapeutics of bronchodilators. Pharmacol Rev. 2012;64:450-504. https://doi.org/10.1124/pr.111.004580 2 Cazzola M Rogliani P Calzetta L Matera MG Bronchodilators in subjects with asthma-related comorbidities Respir Med 2019 151 43 48 https://doi.org/10.1016/j.rmed.2019.04.001 2 Cazzola M, Rogliani P, Calzetta L, Matera MG. Bronchodilators in subjects with asthma-related comorbidities. Respir Med. 2019;151:43-8. https://doi.org/10.1016/j.rmed.2019.04.001 3 Pizzichini MM Carvalho-Pinto RM Cançado JE Rubin AS Cerci A Neto Cardoso AP Recomendações para o manejo da asma da Sociedade Brasileira de Pneumologia e Tisiologia – 2020 J Bras Pneumol 2020 46 e20190307 https://doi.org/10.1590/1806-3713/e20190307 3 Pizzichini MM, Carvalho-Pinto RM, Cançado JE, Rubin AS, Cerci Neto A, Cardoso AP, et al. Recomendações para o manejo da asma da Sociedade Brasileira de Pneumologia e Tisiologia – 2020. J Bras Pneumol. 2020;46:e20190307. https://doi.org/10.1590/1806-3713/e20190307 4 Smith S Edwards CT Long-acting inhaled bronchodilators for cystic fibrosis Paediatr Respir Rev 2018 28 31 32 https://doi.org/10.1016/j.prrv.2018.04.002 4 Smith S, Edwards CT. Long-acting inhaled bronchodilators for cystic fibrosis. Paediatr Respir Rev. 2018;28:31-2. https://doi.org/10.1016/j.prrv.2018.04.002 5 Barry PJ Flume PA Bronchodilators in cystic fibrosis: a critical analysis Expert Rev Respir Med 2017 11 13 20 https://doi.org/10.1080/17476348.2017.1246358 5 Barry PJ, Flume PA. Bronchodilators in cystic fibrosis: a critical analysis. Expert Rev Respir Med. 2017;11:13-20. https://doi.org/10.1080/17476348.2017.1246358 6 Smith S Rowbotham NJ Edwards CT Short-acting inhaled bronchodilators for cystic fibrosis Cochrane Database Syst Rev 2022 6 CD0013666 CD0013666 https://doi.org/10.1002/14651858.CD013666.pub2 6 Smith S, Rowbotham NJ, Edwards CT. Short-acting inhaled bronchodilators for cystic fibrosis. Cochrane Database Syst Rev. 2022;6:CD0013666. https://doi.org/10.1002/14651858.CD013666.pub2 7 Graham BL Steenbruggen I Miller MR Barjaktarevic IZ Cooper BG Hall GL Standardization of spirometry 2019 update an official American Thoracic Society and European Respiratory Society technical statement Am J Respir Crit Care Med 2019 200 e70 e88 https://doi.org/10.1164/rccm.201908-1590ST 7 Graham BL, Steenbruggen I, Miller MR, Barjaktarevic IZ, Cooper BG, Hall GL, et al. Standardization of spirometry 2019 update an official American Thoracic Society and European Respiratory Society technical statement. Am J Respir Crit Care Med. 2019;200:e70-e88. https://doi.org/10.1164/rccm.201908-1590ST 8 Wamosy RM Assumpção MS Parazzi PL Ribeiro JD Roesler H Schivinski CI Reliability of impulse oscillometry parameters in healthy children and in children with cystic fibrosis Int J Clin Pract 2021 75 e13715 https://doi.org/10.1111/ijcp.13715 8 Wamosy RM, Assumpção MS, Parazzi PL, Ribeiro JD, Roesler H, Schivinski CI. Reliability of impulse oscillometry parameters in healthy children and in children with cystic fibrosis. Int J Clin Pract. 2021;75:e13715. https://doi.org/10.1111/ijcp.13715 9 King GG Bates J Berger KI Calverley P Melo PL Dellacà RL Technical standards for respiratory oscillometry Eur Respir J 2020 55 1900753 1900753 https://doi.org/10.1183/13993003.00753-2019 9 King GG, Bates J, Berger KI, Calverley P, Melo PL, Dellacà RL, et al. Technical standards for respiratory oscillometry. Eur Respir J. 2020;55:1900753. https://doi.org/10.1183/13993003.00753-2019 10 Stanojevic S Kaminsky DA Miller M Thompson B Aliverti A Barjaktarevic I ERS/ATS technical standard on interpretive strategies for routine lung function tests Eur Respir J 2022 60 2101499 2101499 https://doi.org/10.1183/13993003.01499-2021 10 Stanojevic S, Kaminsky DA, Miller M, Thompson B, Aliverti A, Barjaktarevic I, et al. ERS/ATS technical standard on interpretive strategies for routine lung function tests. Eur Respir J. 2022;60:2101499. https://doi.org/10.1183/13993003.01499-2021 11 Athanazio RA Silva LV Filho Vergara AA Ribeiro AF Riedi CA Procianoy EF Brazilian guidelines for the diagnosis and treatment of cystic fibrosis J Bras Pneumol 2017 43 219 245 https://doi.org/10.1590/S1806-37562017000000065 11 Athanazio RA, Silva Filho LV, Vergara AA, Ribeiro AF, Riedi CA, Procianoy EF, et al. Brazilian guidelines for the diagnosis and treatment of cystic fibrosis. J Bras Pneumol. 2017;43:219-45. https://doi.org/10.1590/S1806-37562017000000065 12 Kanga J Kuhn R Craigmyle L Haverstock D Church D Cystic fibrosis clinical score: a new scoring system to evaluate acute pulmonary exacerbation Clin Ther 1999 21 1343 1356 https://doi.org/10.1016/s0149-2918(99)80035-6 12 Kanga J, Kuhn R, Craigmyle L, Haverstock D, Church D. Cystic fibrosis clinical score: a new scoring system to evaluate acute pulmonary exacerbation. Clin Ther. 1999;21:1343-56. https://doi.org/10.1016/s0149-2918(99)80035-6 13 Ramsey BW Management of pulmonary disease in patients with cystic fibrosis N Engl J Med 1996 335 179 188 https://doi.org/10.1056/NEJM199607183350307 13 Ramsey BW. Management of pulmonary disease in patients with cystic fibrosis. N Engl J Med. 1996;335:179-88. https://doi.org/10.1056/NEJM199607183350307 14 Doershuk CF Matthews LW Tucker AS Nudelman H Eddy G Wise M A 5 year clinical evaluation of a therapeutic program for patients with cystic fibrosis J Pediatr 1964 65 677 693 https://doi.org/10.1016/s0022-3476(64)80152-9 14 Doershuk CF, Matthews LW, Tucker AS, Nudelman H, Eddy G, Wise M, et al. A 5 year clinical evaluation of a therapeutic program for patients with cystic fibrosis. J Pediatr. 1964;65:677-93. https://doi.org/10.1016/s0022-3476(64)80152-9 15 Onis M Onyango AW Borghi E Siyam A Nishida C Siekmann J Development of a WHO growth reference for school-aged children and adolescents Bull World Health Organ 2007 85 660 667 https://doi.org/10.2471/blt.07.043497 15 Onis M, Onyango AW, Borghi E, Siyam A, Nishida C, Siekmann J. Development of a WHO growth reference for school-aged children and adolescents. Bull World Health Organ. 2007;85:660-7. https://doi.org/10.2471/blt.07.043497 16 Assumpção MS Gonçalves RM Martins R Bobbio TG Schivinski CI Reference equations for impulse oscillometry system parameters in healthy Brazilian children and adolescents Respir Care 2016 61 1090 1099 https://doi.org/10.4187/respcare.04226 16 Assumpção MS, Gonçalves RM, Martins R, Bobbio TG, Schivinski CI. Reference equations for impulse oscillometry system parameters in healthy Brazilian children and adolescents. Respir Care. 2016;61:1090-9. https://doi.org/10.4187/respcare.04226 17 Quanjer PH Stanojevic S Cole TJ Baur X Hall GL Culver BH Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations Eur Respir J 2012 40 1324 1343 https://doi.org/10.1183/09031936.00080312 17 Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, et al. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. Eur Respir J. 2012;40:1324-43. https://doi.org/10.1183/09031936.00080312 18 Muramatu LH Stirbulov R Forte WC Pulmonary function parameters and use of bronchodilators in patients with cystic fibrosis J Bras Pneumol 2013 39 48 55 https://doi.org/10.1590/s1806-37132013000100007 18 Muramatu LH, Stirbulov R, Forte WC. Pulmonary function parameters and use of bronchodilators in patients with cystic fibrosis. J Bras Pneumol. 2013;39:48-55. https://doi.org/10.1590/s1806-37132013000100007 19 Pitrez PM Giavina-Bianchi P Rizzo JA Souza-Machado A Garcia GF Pizzichini MM An expert review on breaking barriers in severe asthma in Brazil: time to act Chron Respir Dis 2021 18 14799731211028259 14799731211028259 https://doi.org/10.1177/14799731211028259 19 Pitrez PM, Giavina-Bianchi P, Rizzo JA, Souza-Machado A, Garcia GF, Pizzichini MM. An expert review on breaking barriers in severe asthma in Brazil: time to act. Chron Respir Dis. 2021;18:14799731211028259. https://doi.org/10.1177/14799731211028259 20 Svenningsen S Nair P Asthma endotypes and an overview of targeted therapy for asthma Front Med (Lausanne) 2017 4 158 158 https://doi.org/10.3389/fmed.2017.00158 20 Svenningsen S, Nair P. Asthma endotypes and an overview of targeted therapy for asthma. Front Med (Lausanne). 2017;4:158. https://doi.org/10.3389/fmed.2017.00158 21 Galant SP Komarow HD Shin HW Siddiqui S Lipworth BJ The case for impulse oscillometry in the management of asthma in children and adults Ann Allergy Asthma Immunol 2017 118 664 671 https://doi.org/10.1016/j.anai.2017.04.009 21 Galant SP, Komarow HD, Shin HW, Siddiqui S, Lipworth BJ. The case for impulse oscillometry in the management of asthma in children and adults. Ann Allergy Asthma Immunol. 2017;118:664-71. https://doi.org/10.1016/j.anai.2017.04.009 22 Shin YH Jang SJ Yoon JW Jee HM Choi SH Yum HY Oscillometric and spirometric bronchodilator response in preschool children with and without asthma Can Respir J 2012 19 273 277 https://doi.org/10.1155/2012/560323 22 Shin YH, Jang SJ, Yoon JW, Jee HM, Choi SH, Yum HY, et al. Oscillometric and spirometric bronchodilator response in preschool children with and without asthma. Can Respir J. 2012;19:273-7. https://doi.org/10.1155/2012/560323 23 Hellinckx J Boeck K Demedts M No paradoxical bronchodilator response with forced oscillation technique in children with cystic fibrosis Chest 1998 113 55 59 https://doi.org/10.1378/chest.113.1.55 23 Hellinckx J, Boeck K, Demedts M. No paradoxical bronchodilator response with forced oscillation technique in children with cystic fibrosis. Chest. 1998;113:55-9. https://doi.org/10.1378/chest.113.1.55 24 Öztürk GK Eşki A Gülen F Demir E Is impulse oscillometry system a useful method for the evaluation and follow-up of patients with cystic fibrosis? Pediatr Allergy Immunol Pulmonol 2021 34 15 22 https://doi.org/10.1089/ped.2020.1317 24 Öztürk GK, Eşki A, Gülen F, Demir E. Is impulse oscillometry system a useful method for the evaluation and follow-up of patients with cystic fibrosis? Pediatr Allergy Immunol Pulmonol. 2021;34:15-22. https://doi.org/10.1089/ped.2020.1317 25 Miller MR Hankinson J Brusasco V Burgos F Casaburi R Coates A Standardisation of spirometry Eur Respir J 2005 26 319 338 https://doi.org/10.1183/09031936.05.00034805 25 Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Respir J. 2005;26:319-38. https://doi.org/10.1183/09031936.05.00034805 26 Oliveira Jorge PP Lima JH Chong e Silva DC Medeiros D Solé D Wandalsen GF Impulse oscillometry in the assessment of children's lung function Allergol Immunopathol (Madr) 2019 47 295 302 https://doi.org/10.1016/j.aller.2018.03.003 26 Oliveira Jorge PP, Lima JH, Chong e Silva DC, Medeiros D, Solé D, Wandalsen GF. Impulse oscillometry in the assessment of children's lung function. Allergol Immunopathol (Madr). 2019;47:295-302. https://doi.org/10.1016/j.aller.2018.03.003 27 Marion CR Izquierdo M Hanes HC Barrios C Asthma in cystic fibrosis: definitions and implications of this overlap syndrome Curr Allergy Asthma Rep 2021 21 9 9 https://doi.org/10.1007/s11882-020-00985-7 27 Marion CR, Izquierdo M, Hanes HC, Barrios C. Asthma in cystic fibrosis: definitions and implications of this overlap syndrome. Curr Allergy Asthma Rep. 2021;21:9. https://doi.org/10.1007/s11882-020-00985-7